PMA Panel Asks TherOx For New Data On Cath-Lab-Based Oxygen Therapy
This article was originally published in The Gray Sheet
Executive Summary
FDA's Circulatory System Devices advisory panel is encouraging TherOx to sponsor a new clinical trial of its SSO2 SuperSaturated Oxygen Therapy Downstream system to demonstrate the therapy improves clinical outcomes in heart attack patients